Is a blood test for multiple cancers hope or hype?


Is a blood test for multiple cancers hope or hype?

Either way, the potential benefit is big enough to make worthwhile the work and cost involved to find out

Max Nisen

More than half a million Americans die of cancer each year, matching the toll of Covid-19 to date on an annual basis and making it one of the nation’s biggest killers. But now there’s hope that a simple blood test could change that by detecting tumours earlier, when they’re easier to treat. 

Grail, a biotechnology start-up, launched a blood test called Galleri in the US in June and published data validating its ability to detect otherwise hard-to-find tumours. While blood tests already exist for individual cancers, Grail’s caught 29 different types of the disease in a real-world experiment. If these tests prove effective, they could slash cancer’s burden, so unsurprisingly the news received a lot of attention. But is it more hype than hope? There’s promise, for sure. It’s essential, though, to acknowledge some realities of cancer screening that may hold these tests back. 

It seems obvious that we ought to search for and catch as many cancers as possible, right? Well, not exactly. As counterintuitive as this may sound, that strategy can be wasteful and even harmful on a population level. The history of cancer testing includes life-saving successes, such as pap smears for cervical cancer, but also costly misses, such as prostate and thyroid screening, which don’t always have strong benefits. The result is that we routinely look for only a few cancers...

This article is free to read if you register or sign in.

Sunday Times Daily

If you have already registered or subscribed, please sign in to continue.

Questions or problems?
Email or call 0860 52 52 00.

Next Article

Previous Article